相关实验视频
Updated: Jan 15, 2026

A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats
Published on: February 20, 2021
在ICU患者中中性贫血性败血症和败血性休克:在过去十年中,一个单一中心的经验
Florian Guillotin1, Laetitia Aubert2, Soraya Benguerfi1,3
1Service de Médecine Intensive Réanimation, CHU de Nantes, Nantes Université, Nantes, France.
中性贫血性败血症患者年龄较大,并发病率较高,但死亡率显示非显著下降. 建议在ICU入院后进行组合抗生素治疗,包括氨基甘油,以获得更好的结果.
科学领域:
- 关键护理医学 关键护理医学
- 传染性疾病 传染性疾病
- 血液学 瘤学 癌症学
背景情况:
- 中性贫血性败血症和败血性休克的死亡率很高.
- 了解不断变化的患者人口统计和结果预测因素对于改善护理至关重要.
研究的目的:
- 在十年内调查中性衰竭性败血症的临床特征和死亡率预测因素.
- 为了比较两个不同的时间段之间的患者特征和结果.
主要方法:
- 在2012-2022年期间,对重症监护病房 (ICU) 中发生中性衰减和败血症/败血性休克的患者进行了回顾性分析.
- 2012-2017年和2018-2022年队列之间的患者数据的比较.
- 单变量和多变量分析以确定住院死亡预测因素.
主要成果:
- 最近的队列 (2018-2022) 包括老年患者与较早的队列 (2012-2017) 相比,具有更高的并发症负担.
- 最近一组的住院死亡率为40.0%,而早期一组的死亡率为49.4% (p=0.24).
- 年龄较大,较高的SOFA得分预测死亡率,而氨基糖化物治疗与较低的死亡率有关.
结论:
- 尽管患者年龄和并发症增加,但观察到中性贫血性败血症的死亡率下降的趋势.
- 结合抗生素治疗,包括在ICU入院时使用氨基糖化物,得到了研究结果的支持.
- 早期的源控制干预没有显著影响死亡率.
更多相关视频
07:30Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
Published on: June 15, 2019
05:52Author Spotlight: Induction of Experimental Endotoxemic Shock in Pigs for Studying Hemodynamic and Respiratory Failure
Published on: December 8, 2023
相关概念视频
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.
Acute Pyelonephritis II: Diagnostic Studies and Management
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment
Acute Kidney Injury IV: Diagnostic Studies and Prevention